Related Experiment Video

Updated: Feb 18, 2026

A Simplified Model for Heterotopic Heart Valve Transplantation in Rodents
06:33

A Simplified Model for Heterotopic Heart Valve Transplantation in Rodents

Published on: September 21, 2021

2.8K

Use of prostaglandins in duct-dependent congenital heart conditions

Yogen Singh1, Paraskevi Mikrou2

  • 1Department of Neonatology and Paediatric Cardiology, Cambridge University Hospitals NHS Foundation Trust and University of Cambridge, Cambridge, UK.

Archives of Disease in Childhood. Education and Practice Edition
|November 23, 2017
PubMed

Insights

Undiagnosed critical congenital heart disease (CHD) poses a high risk to infants. Prompt prostaglandin treatment is vital for maintaining ductal patency in duct-dependent CHDs to prevent mortality.

Area of Science:

  • Pediatrics
  • Cardiology
  • Neonatology

Background:

  • Congenital heart disease (CHD) is a major cause of infant mortality.
  • Duct-dependent CHDs can lead to severe deterioration after birth when the ductus arteriosus closes.
  • A significant percentage of infants with critical CHD are discharged undiagnosed.

Purpose of the Study:

  • To highlight the critical importance of maintaining ductal patency in infants with duct-dependent CHDs.
  • To emphasize the role of prostaglandins in managing these conditions.
  • To underscore the need for timely diagnosis and intervention.

Main Methods:

  • Review of clinical presentations and management strategies for duct-dependent CHDs.
  • Discussion of prostaglandin (E1 and E2) use for maintaining ductus arteriosus patency.
  • Emphasis on the clinical significance of prompt treatment initiation.

Main Results:

  • Delay in prostaglandin infusion can have severe, even fatal, consequences for infants.
  • Effective management requires a thorough understanding of CHD and ductal patency medications.
  • Early diagnosis and intervention are crucial for improving infant outcomes.

Conclusions:

  • Maintaining ductal patency with prostaglandins is critical for infants with duct-dependent CHDs.
  • Timely administration of prostaglandin infusions is essential to prevent adverse outcomes.
  • Healthcare professionals must possess expertise in managing these emergencies.

Keywords:
congenital heart defectsdinoprostone/alprostadilduct dependentductus arteriosusprostaglandin

More Related Videos

Implantation of Total Artificial Heart in Congenital Heart Disease07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

25.3K
Transuterine Fetal Tracheal Occlusion Model in Mice06:31

Transuterine Fetal Tracheal Occlusion Model in Mice

Published on: February 5, 2021

3.6K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
529
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.3K
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
322
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
810
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
393
Mitral Valve Prolapse I: Introduction01:27

Mitral Valve Prolapse I: Introduction

IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
625